PlainPharmaWatch

CMS Open Payments · Tool

Orthalign Inc vs Olympus America Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Orthalign Inc has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,006, versus 133 for the other company. Its single largest recorded recipient represents 16.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Orthalign Inc
HHI 1,006 · top recipient 16.3%
Ranked #1,027 of 1,838 companies by HHI
Olympus America Inc.
HHI 133 · top recipient 6.4%
Ranked #1,641 of 1,838 companies by HHI

Payment Overview

Company A

Orthalign Inc

Total Payments
$2.8M
% of Industry
0.0%
Transactions
721
Avg per Transaction
$3.9K
Recipients
713
Avg per Recipient
$4.0K
Payment Types
4
Top Payment Type
Royalty or License
Total Payments
$2.8M
% of Industry
0.0%
Transactions
7,547
Avg per Transaction
$372.72
Recipients
7,547
Avg per Recipient
$372.72
Payment Types
8
Top Payment Type
Debt Forgiveness

Highlighted values indicate the higher figure for each metric.

Total payments compared

Orthalign Inc vs Olympus America Inc. - total reported payments in CMS Open Payments PY2024

Orthalign Inc$2.8MOlympus America Inc.$2.8M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Orthalign Inc

Royalty or License $1.3M

85.7%

Consulting Fee $137.1K

9.3%

Food and Beverage $50.7K

3.4%

Travel and Lodging $24.1K

1.6%

Olympus America Inc.

Debt Forgiveness $1.9M

68.9%

Food and Beverage $253.2K

9.0%

Consulting Fee $245.2K

8.7%

Compensation for Services Other Than Consulting $197.2K

7.0%

Space Rental or Facility Fees $128.0K

4.6%

Travel and Lodging $27.1K

1.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Orthalign Inc

  1. 1

    DAVID MAYMAN

    $241,138.78 · 5 txns

  2. 2

    MICHAEL PAUL AST

    $235,372.62 · 11 txns

  3. 3

    STEVEN B HAAS

    $160,792.19 · 5 txns

  4. 4

    FRED D CUSHNER

    $160,791.28 · 5 txns

  5. 5

    William D Bugbee

    $157,054.67 · 4 txns

Olympus America Inc.

  1. 1

    U Of U Hospitals & Clinics

    $179,641.96 · 26 txns

  2. 2

    BRADLEY A JABOUR

    $153,023.47 · 1 txns

  3. 3

    Mount Sinai Hospital

    $93,721.05 · 6 txns

  4. 4

    Adebambo Oladele Ojuri

    $74,784.17 · 1 txns

  5. 5

    Trident Regional Medical Center

    $51,020.96 · 2 txns

Summary Comparison

Metric Orthalign Inc Olympus America Inc.
Total Payments $2.8M $2.8M
% of Industry Total 0.0% 0.0%
Transaction Count 721 7,547
Avg per Transaction $3.9K $372.72
Recipient Count 713 7,547
Avg per Recipient $4.0K $372.72
Payment Type Count 4 8
Top Payment Type Royalty or License Debt Forgiveness

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.